Expression and mutation analysis of her2 in head and neck squamous cell carcinoma

Cancer Investigation

Volumn 28, Issue 5, 2010, Pages 495-500

  Ali, Mahmoud Al Sheikh ^a   Gunduz, Mehmet ^a,b,c   Gunduz, Esra ^a,c   Tamamura, Ryo ^a   Beder, Levent Bekir ^b   Katase, Naoki ^a   Hatipoglu, Omer Faruk ^a   Fukushima, Kunihiro ^a   Yamanaka, Noboru ^b   Shimizu, Kenji ^a   Nagatsuka, Hitoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c FATIH UNIVERSITY   (Turkey)

Author keywords

Head and neck cancer; Her2; Immunohistochemistry; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC ASSOCIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77952213693     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900903476778     Document Type: Article

References (20)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55, 74-108.
2. Klapper, L.N.; Glathe, S.; Vaisman, N.; Hynes, N.E.; Andrews, G.C.; Sela, M.; Yarden, Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999, 96(9), 4995-5000.
3. Graus-Porta, D.; Beerli, R.R.; Daly, J.M.; Hynes, N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16(7), 1647-1655.
4. Sheikh Ali, M.; Gunduz, M.; Nagatsuka, H.; Gunduz, E.; Cengiz, B.; Fukushima, K.; Beder, L.B.; Demircan, K.; Fujii, M.; Yamanaka, N.; Shimizu, K.; Grenman, R.; Nagai, N. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008, 99(8), 1589-1594.
5. Buttitta, F.; Barassi, F.; Fresu, G.; Felicioni, L.; Chella, A.; Paolizzi, D.; Lattanzio, G.; Salvatore, S.; Camplese, P.P.; Rosini, S.; Iarussi, T.; Mucilli, F.; Sacco, R.; Mezzetti, A.; Marchetti, A. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006, 119(11), 2586-2591.
6. Gunduz, M.; Ouchida, M.; Fukushima, K.; Ito, S.; Jitsumori, Y.; Nakashima, T.; Nagai, N.; Nishizaki, K.; Shimizu, K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 2002, 21, 4462-4470.
7. Uno, M.; Otsuki, T.; Kurebayashi, J.; Sakaguchi, H.; Isozaki, Y.; Ueki, A.; Yata, K.; Fujii, T.; Hiratsuka, J.; Akisada, T.; Harada, T.; Imajo, Y. Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int J Cancer 2001, 94(4), 474-479.
8. Hirata, A.; Hosoi, F.; Miyagawa, M.; Ueda, S.; Naito, S.; Fujii, T.; Kuwano, M.; Ono, M. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005, 65(10), 4253-4260.
9. Cavalot, A.; Martone, T.; Roggero, N.; Brondino, G.; Pagano, M.; Cortesina, G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007, 29(7):655-664.
10. Gullick, W.J.; Hughes, C.M.; Mellon, K.; Neal, D.E.; Lemoine, N.R. Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol 1991, 164(4), 285-289.
11. Ḿenard, S.; Casalini, P.; Campiglio, M.; Pupa, S.M.; Tagliabue, E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004, 61(23), 2965-2978.
12. Schartinger, V.H.; Kacani, L.; Andrle, J.; Schwentner, I.; Wurm, M.; Obrist, P.; Oberaigner, W.; Sprinzl, G.M. Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma ORL. J Otorhinolaryngol Relat Spec 2004, 66(1), 21-26.
13. Kearsley, J.H.; Leonard, J.H.; Walsh, M.D.; Wright, G.R. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 1991, 23(3), 189-194.
14. Craven, J.M.; Pavelic, Z.P.; Stambrook, P.J.; Pavelic, L.; Gapany, M.; Kelley, D.J.; Gapany, S.; Gluckman, J.L. Expression of c-erbB- 2 gene in human head and neck carcinoma. Anticancer Res 1992, 12(6B), 2273-2276.
15. Ibrahim, S.O.; Vasstrand, E.N.; Liavaag, P.G.; Johannessen, A.C.; Lillehaug, J.R. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997, 17(6D), 4539-4546.
16. Khan, A.J.; King, B.L.; Smith, B.D.; Smith, G.L.; DiGiovanna, M.P.; Carter, D.; Haffty, B.G. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 2002, 8(2), 540-548.
17. Smilek, P.; Dusek, L.; Veseĺy, K.; Rottenberg, J.; Kostrica, R. Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. J Exp Clin Cancer Res 2006, 25(4), 549-555.
18. Baselga, J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2002, 2(2), 93-95.
19. Willmore-Payne, C.; Holden, J.A.; Layfield, L.J. Detection of EGFRand HER2-activatingmutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006, 19(5), 634-640.
20. Erjala, K.; Sundvall, M.; Junttila, T.T.; Zhang, N.; Savisalo, M.; Mali, P.; Kulmala, J.; Pulkkinen, J.; Grenman, R.; Elenius, K. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006, 12(13), 4103-4111.